Canaccord Genuity Reiterates Hold on Zimmer Biomet Holdings, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Caitlin Cronin reiterated a Hold rating on Zimmer Biomet Holdings (ZBH) and maintained a $130 price target.
February 23, 2024 | 3:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Hold rating and a $130 price target for Zimmer Biomet Holdings.
The reiteration of the Hold rating and maintenance of the price target by a reputable analyst suggests a neutral short-term impact on ZBH's stock price. The analyst's view likely reflects a balanced outlook on the company's performance, without significant positive or negative catalysts in the near term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100